Medtronic expands pain management portfolio with $650 million acquisition of SPR Therapeutics

Medtronic has announced its intent to acquire medical technology firm SPR Therapeutics for an upfront cash payment of approximately $650 million. The deal will integrate a short-term, minimally invasive peripheral nerve stimulation system into Medtronic's neuromodulation business during the first half of its fiscal year 2027.

Medtronic plc has agreed to purchase 100 percent of the outstanding equity of SPR Therapeutics, Inc. for an upfront cash consideration of roughly $650 million. According to official disclosures, the transaction is projected to conclude within the first half of Medtronic's fiscal year 2027, which commenced on April 25, 2026. Both entities will operate independently until standard regulatory evaluations and closing conditions are finalized. Medtronic is a global medical device and healthcare technology conglomerate, whereas SPR Therapeutics is a private firm that engineers temporary, percutaneous peripheral nerve stimulation equipment used to manage chronic discomfort.

This transaction accelerates Medtronic's expansion into early-stage, non-permanent pain interventions. The target's flagship product provides a 60-day temporary treatment cycle that avoids the complications of permanent surgical implants. Integrating this technology allows Medtronic to capture market share earlier in the patient care lifecycle and address a domestic patient base numbering tens of millions. For the broader medical hardware and healthcare provider sectors, this deal underlines a significant shift toward non-addictive, less-invasive pain therapies. Demand for alternative treatments is intensifying as clinical networks and regulatory bodies deprioritize long-term opioid prescriptions.

The acquisition gives Medtronic an asset that integrates into existing clinical workflows and carries favorable reimbursement structures. For institutional investors and healthcare analysts, the transaction reflects a deliberate capital allocation strategy aimed at scaling core neuromodulation lines through targeted acquisitions. By utilizing its global distribution networks, Medtronic can rapidly scale a therapy that boasts high real-world efficacy rates. This commercial scale will help diversify its primary medical portfolios, driving reliable revenue streams within a highly lucrative segment of the medical equipment sector.